Ac­celeron scraps dalanter­cept af­ter it flunks a PhII test for kid­ney can­cer

Ac­celeron will not be get­ting any help from dalanter­cept as it works to build con­fi­dence in its pipeline.

The Cam­bridge, MA-based biotech says their an­gio­gen­e­sis drug flopped in a Phase II study for kid­ney can­cer that en­rolled 131 pa­tients. Not on­ly was their no sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for their drug com­bined with ax­i­tinib, ver­sus the stan­dard of care alone, the con­firmed ob­jec­tive re­sponse rate was a lit­tle low­er for Ac­celeron’s drug — 19% com­pared to 25% for the con­trol arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER